Medicare Coverage for Head and Neck Cancer: Surgery, Radiation, Chemotherapy, and Rehab

Head and neck cancers—encompassing cancers of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, salivary glands, and thyroid—affect more than 66,000 Americans per year. While many cases occur in adults under 65, the incidence rises sharply after age 55, and a significant proportion of patients are Medicare beneficiaries. Treatment is often multimodal—combining surgery, radiation, and chemotherapy—which means multiple Medicare benefit categories come into play simultaneously. The financial stakes are high: without supplemental coverage, a head and neck cancer treatment course can generate tens of thousands of dollars in unreimbursed cost-sharing under original Medicare.

What Medicare Covers for Diagnosis

Office Visits and Examination

Initial evaluation by an otolaryngologist (ENT), head and neck surgeon, or oral and maxillofacial surgeon is covered under Part B as a physician office visit. You pay 20 percent coinsurance after the $257 Part B deductible (2026).

Diagnostic Imaging

All standard diagnostic imaging is covered under Part B at 20 percent coinsurance:

• CT scan of the neck with contrast: For evaluating primary tumor extent and cervical lymph node involvement
• PET-CT (PET scan): Covered under Part B for initial staging of head and neck cancer, post-treatment surveillance, and detecting recurrence. Medicare covers PET-CT for all solid tumors when used in staging or restaging.
• MRI of the head and neck: For soft tissue characterization, perineural invasion, and skull base involvement
• Panoramic dental X-ray (OPG): Often required before radiation to plan dental extractions; covered under Part B as a diagnostic service (not a dental procedure)

Note: Medicare does not cover routine dental care, but dental evaluations and extractions performed as part of cancer treatment preparation may be covered. The rule is nuanced—see Medicare Dental Vision Hearing Coverage for details.

Biopsy and Pathology

Biopsies of suspicious lesions—whether performed via direct laryngoscopy, fiber-optic examination, fine needle aspiration (FNA) of lymph nodes, or punch biopsy of oral lesions—are covered under Part B:

• Fine needle aspiration biopsy: Office or ultrasound-guided FNA of neck masses; 20 percent coinsurance
• Core needle biopsy: Ultrasound-guided core biopsy of neck nodes; 20 percent coinsurance
• Panendoscopy with biopsy: Direct laryngoscopy, esophagoscopy, and bronchoscopy performed under general anesthesia to identify primary tumor and synchronous lesions; covered under Part B or Part A depending on admission status
• Pathology fees: Clinical laboratory charges for specimen analysis are billed at zero coinsurance

HPV Testing

For oropharyngeal cancers (tonsil, base of tongue), HPV status is an important prognostic marker. HPV testing performed on biopsy tissue is covered under Part B as a clinical laboratory service.

Surgery

Head and neck surgery ranges from minor outpatient excisions to complex ablative and reconstructive procedures requiring prolonged hospitalization.

Minor Outpatient Surgery

Small oral lesions, early-stage laryngeal cancers treated with laser cordectomy, and selected salivary gland tumors may be managed with outpatient surgical procedures under Part B:

• Facility fee: 20 percent coinsurance at a hospital outpatient department (HOPD) or ambulatory surgery center (ASC)
• Surgeon fee: 20 percent coinsurance (separate Part B claim)

Major Inpatient Surgery

For larger resections—partial or total laryngectomy, glossectomy, mandibulectomy, maxillectomy, parotidectomy, or neck dissection—inpatient admission under Part A is typical:

• Part A hospital deductible: $1,676 per benefit period in 2026
• Days 1–60: Only the deductible, no daily coinsurance
• Days 61–90: $419/day coinsurance
• Surgeon and anesthesiologist fees: Billed separately under Part B (20 percent coinsurance)

Reconstructive Surgery and Free Flaps

Complex head and neck reconstruction using microvascular free tissue transfer (free flaps from the forearm, thigh, fibula, or scapula) is covered under Medicare when medically necessary following cancer ablation. These are some of the most technically demanding procedures in surgery, typically requiring 6–12 hours in the operating room and 5–14 days of inpatient recovery. Coverage falls under Part A (facility) and Part B (surgeon).

Neck Dissection

Selective neck dissection—removal of cervical lymph node groups at risk—is frequently performed simultaneously with primary tumor resection or as a staged procedure. It is covered under Part A (inpatient) or Part B (outpatient) depending on how the surgical hospitalization is classified.

Tracheostomy and Laryngectomy Supplies

Patients who require a total laryngectomy receive a permanent tracheostoma. Medicare covers laryngectomy supplies as durable medical equipment (DME) under Part B:

• Heat and moisture exchangers (HMEs) / artificial noses
• Laryngectomy tubes
• Speaking valves (tracheoesophageal prostheses—TEP) and base plates
• Stoma covers

DME is covered at 80 percent by Medicare (20 percent coinsurance after the deductible). A Medigap supplement covers this coinsurance.

Radiation Therapy

Radiation is used as primary treatment for many oropharyngeal, laryngeal, and nasopharyngeal cancers, and as post-operative adjuvant treatment following surgery for advanced-stage disease. All forms of radiation are covered under Part B as outpatient services.

Intensity-Modulated Radiation Therapy (IMRT)

IMRT is the standard radiation technique for head and neck cancers because it can spare the parotid glands from high doses, reducing long-term xerostomia (dry mouth). A typical course involves 35 daily fractions over 7 weeks (70 Gy total), with each fraction being a separate Part B claim:

• Per-fraction charge (facility + physician): Approximately $500–$1,000 per fraction in Medicare-approved amounts
• 35-fraction course: Approximately $17,500–$35,000 in total Medicare-approved charges
• Your 20 percent coinsurance without supplemental coverage: $3,500–$7,000 for the radiation course alone

Stereotactic Radiosurgery (SRS) and SBRT

For selected patients—nasopharyngeal boost doses, recurrent disease, or oligometastatic nodes—stereotactic techniques deliver high doses in fewer fractions (typically 5 or fewer). Medicare covers SRS/SBRT under Part B.

Proton Therapy

Proton beam therapy for head and neck cancers may offer dosimetric advantages in selected anatomical locations (e.g., skull base tumors, pediatric-type nasopharyngeal carcinoma). Medicare covers proton therapy under Part B, subject to 20 percent coinsurance. As noted in Medicare Cancer Treatment Coverage, the coinsurance on high-cost proton courses can be substantial without Medigap Plan G.

Concurrent Chemoradiation

Most locally advanced head and neck cancers (Stage III–IVB) are treated with concurrent cisplatin-based chemoradiation—chemotherapy administered during radiation to sensitize tumors. This is the standard of care endorsed by the National Comprehensive Cancer Network (NCCN) and is covered by Medicare across its benefit categories:

• Radiation therapy: Part B outpatient
• Cisplatin IV infusion: Part B infusion drug (see below)

Chemotherapy and Systemic Therapy

Cisplatin (Part B)

Cisplatin is the standard radiosensitizing chemotherapy agent for head and neck cancers. It is administered intravenously, typically in a hospital outpatient infusion center or physician’s office infusion suite, and is billed as a Part B drug:

• High-dose weekly cisplatin (40 mg/m²) or every-3-week cisplatin (100 mg/m²) during radiation
• Medicare covers the drug cost plus the infusion administration fee
• Your 20 percent coinsurance applies to both the drug and administration

Cisplatin is a generic platinum compound with a low per-dose cost (typically $50–$200 in Medicare-approved drug amounts), so the coinsurance per infusion is modest. The infusion facility fee is the larger cost component.

Carboplatin

For patients who cannot tolerate cisplatin (due to renal dysfunction, hearing loss, or neuropathy), carboplatin is a less nephrotoxic alternative. Also a Part B drug with similar low per-dose cost.

Taxane Combinations

Docetaxel and paclitaxel are used in induction chemotherapy regimens (TPF protocol: taxane + platinum + 5-fluorouracil) and in recurrent/metastatic disease. Both are Part B IV infusion drugs subject to 20 percent coinsurance.

5-Fluorouracil (5-FU): Administered as a continuous IV infusion over 4–5 days during concurrent chemoradiation or in recurrent/metastatic regimens. Part B drug.

Cetuximab (Erbitux) — Part B

Cetuximab is an epidermal growth factor receptor (EGFR) monoclonal antibody used as an alternative to cisplatin for concurrent chemoradiation and in recurrent/metastatic disease. It is administered by IV infusion and billed as a Part B drug.

The Medicare-approved amount for cetuximab is approximately $5,000–$8,000 per infusion cycle, making it one of the highest-cost drugs in head and neck cancer treatment:

• 7-week concurrent chemoradiation course: 8 weekly infusions × $5,000–$8,000 = $40,000–$64,000 in Medicare-approved charges
• Your 20 percent coinsurance without supplemental coverage: $8,000–$12,800 for cetuximab alone

For patients receiving cetuximab concurrently with radiation, the combination of radiation coinsurance and cetuximab coinsurance can generate $12,000–$20,000 in out-of-pocket costs under original Medicare. Medigap Plan G eliminates all of this coinsurance beyond the $257 annual deductible.

Pembrolizumab (Keytruda) — Part B

The KEYNOTE-048 trial established pembrolizumab-based regimens as a first-line standard of care for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Medicare covers pembrolizumab under Part B as an IV infusion drug:

• Pembrolizumab is administered every 3 or 6 weeks
• Medicare-approved amount per infusion: approximately $8,000–$12,000
• Your 20 percent coinsurance without supplemental coverage: $1,600–$2,400 per infusion, with no annual cap under original Medicare

Pembrolizumab may be used for years in responders, meaning total coinsurance exposure can exceed $20,000–$40,000 annually. This is precisely the scenario where Medigap Plan G, which eliminates all Part B coinsurance, provides its greatest value. See Medigap Plans Compared for a full cost analysis.

Nivolumab (Opdivo) — Part B

Nivolumab (anti-PD-1) is approved for platinum-refractory R/M SCCHN. Also a Part B IV infusion drug with similar cost-sharing to pembrolizumab.

Feeding Tube and Nutritional Support

Head and neck cancer treatment frequently causes severe mucositis, dysphagia, and pain that impair oral intake, necessitating enteral nutrition support.

PEG Tube Placement

Percutaneous endoscopic gastrostomy (PEG) tube placement is covered under Part B as an outpatient procedure (20 percent coinsurance) or under Part A if performed during an inpatient hospitalization.

Enteral Nutrition via DME

For patients who require tube feeding at home, Medicare covers enteral nutrition formulas and supplies through the DME benefit under Part B when a patient has a functional gastrointestinal tract but cannot eat orally due to cancer or its treatment. Coverage requires documentation that the tube feeding is the patient’s primary means of nutrition (not supplemental). DME coverage applies 80/20 (you pay 20 percent coinsurance).

Speech-Language Pathology (SLP) and Swallowing Therapy

Dysphagia—difficulty swallowing—is among the most debilitating long-term effects of head and neck cancer treatment, affecting 30–50 percent of survivors. Swallowing rehabilitation is a major component of post-treatment care and is covered under Medicare.

Outpatient Speech Therapy

Speech-language pathology (SLP) services are covered under Part B as outpatient therapy:

• Swallowing evaluation (modified barium swallow study or fiberoptic endoscopic evaluation of swallowing, FEES)
• Swallowing rehabilitation exercises
• Voice therapy for laryngeal cancer survivors
• Alaryngeal speech training (tracheoesophageal voice prosthesis, electrolarynx use, esophageal speech) for laryngectomy patients

The Jimmo v. Sebelius settlement confirmed that Medicare covers maintenance therapy—continued SLP sessions to maintain function and prevent deterioration—not just restorative therapy aimed at improvement. This is critical for dysphagia patients whose swallowing function may plateau but requires ongoing maintenance to prevent aspiration.

There is no hard annual dollar cap on Part B outpatient therapy. A $2,330 threshold (2026 KX modifier threshold) triggers additional documentation, but medically necessary therapy above this amount is covered when the KX modifier is attached and documentation supports the medical necessity.

Inpatient and SNF-Based SLP

If a patient requires inpatient rehabilitation following major head and neck surgery, SLP services are covered as part of the inpatient rehab facility (IRF) per-diem under Part A. In a skilled nursing facility (SNF), SLP is covered under Part A skilled nursing days 1–100 (with daily coinsurance after day 20).

Dental Rehabilitation

Dental restoration following radiation-induced xerostomia and radiation caries is not generally covered by Medicare. However, a small number of Medicare Advantage plans offer supplemental dental benefits. See Medicare Dental Vision Hearing Coverage for the coverage gap details.

Inpatient Rehabilitation (IRF)

Following major head and neck surgery, patients who require intensive multidisciplinary rehabilitation—combining physical therapy, occupational therapy, and speech-language pathology—may qualify for admission to an inpatient rehabilitation facility (IRF). Head and neck cancer is among the qualifying conditions for IRF admission, provided the patient can tolerate 3 hours of therapy per day and requires physician supervision.

IRF coverage falls under Part A:

• Part A deductible: $1,676 per benefit period (may be a new benefit period if more than 60 days have elapsed since the surgical admission)
• Days 21–60: $419/day coinsurance
• Days 61–90: $838/day coinsurance

Medigap Plan G: Covers the Part A deductible and all daily coinsurance for IRF stays, in addition to Part B drug coinsurance.

Home Health After Cancer Treatment

Patients who are homebound following head and neck cancer surgery or intensive chemoradiation may qualify for Medicare home health services under Part A or Part B (billed at zero patient cost-sharing):

• Skilled nursing visits (wound care, tracheostomy care, tube feeding management)
• Physical therapy for deconditioning
• Occupational therapy for upper extremity weakness or function
• Speech-language pathology for swallowing evaluation and rehab
• Home health aide services (personal care) when skilled care is also occurring

Home health is covered at zero cost-sharing when the patient meets homebound criteria and a physician certifies a skilled care plan.

Cost Comparison: Original Medicare vs. Plan G vs. Medicare Advantage

Illustrative cost scenario: A Medicare beneficiary with Stage III oropharyngeal cancer treated with concurrent cetuximab-based chemoradiation (7 weeks, 35 IMRT fractions, 8 cetuximab infusions), followed by 6 months of pembrolizumab maintenance, and 40 outpatient SLP sessions.

For this patient, Medigap Plan G would save approximately $28,000 in a single year compared to original Medicare alone. Annual Plan G premiums range from $1,400–$3,600 depending on age and location—a fraction of the coverage value in a cancer treatment year.

For Medicare Advantage, total cost depends on the plan’s out-of-pocket maximum (up to $8,850 in-network for 2026), prior authorization outcomes, and network access to specialty oncology centers.

Getting the Most from Medicare for Head and Neck Cancer

1. Enroll in Medigap Plan G if you haven’t already: The unlimited coinsurance exposure under original Medicare on Part B drugs (cetuximab, pembrolizumab, cisplatin infusions) makes Plan G essential for cancer patients. Outside the guaranteed-issue window, medical underwriting may apply—apply before a diagnosis if possible.

2. Verify MA network access before treatment begins: If enrolled in MA, confirm that your head and neck surgeon, radiation oncologist, and medical oncologist are all in-network. Major cancer centers (MD Anderson, Memorial Sloan Kettering, Mayo Clinic) are often out-of-network for regional MA plans.

3. Request prior authorization early: For MA plans, initiate the PA process for surgery, radiation, and infusion drugs as soon as the treatment plan is established. Appeals of PA denials are a legal right; appeal immediately and request expedited review for urgent clinical needs.

4. Explore clinical trials: Medicare covers routine care costs associated with approved clinical trials. For recurrent/refractory disease, clinical trial access may offer novel treatments with Medicare covering the standard-of-care component costs.

5. Low-income assistance: If your income is modest, Extra Help for Part D and QMB/SLMB for Part B premiums and cost-sharing can dramatically reduce your financial exposure. See Medicare Savings Programs and Healthcare Costs in Retirement for a complete overview of available assistance.